ISTANBUL, Sept. 14 /PRNewswire-FirstCall/ -- Schering-Plough Corporation
(NYSE: SGP) today reported final results of a SAPHRIS(R) (asenapine) long-term
schizophrenia relapse prevention clinical study. In the double-blind phase of
the study, time to relapse or impending relapse, the primary efficacy
endpoint, was significantly longer with SAPHRIS than with placebo (P <
0.0001). At the end of the double-blind phase, significantly fewer patients
had relapsed with SAPHRIS than with placebo, 12 percent vs. 47 percent (P <
0.0001). In addition, the time to treatment discontinuation for any reason, a
secondary efficacy assessment, was significantly longer with SAPHRIS than
placebo (P < 0.001). These results were presented at a major European
psychiatry congress in Istanbul, Turkey.
